| Identification | Back Directory | [Name]
Taspoglutide | [CAS]
275371-94-3 | [Synonyms]
R-1583
ITM-077
BIM-51077
taspoglutide
Taspoglutide Acetate
ITM-077;R-1583;BIM-51077
7-36-Glucagon-like peptide I (human), 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide- | [Molecular Formula]
C152H232N40O45 | [MDL Number]
MFCD13195564 | [MOL File]
275371-94-3.mol | [Molecular Weight]
3339.71 |
| Chemical Properties | Back Directory | [density ]
1.46 | [storage temp. ]
-20°C | [solubility ]
DMSO : ≥ 28 mg/mL (8.38 mM) | [form ]
lyophilized powder | [color ]
white to beige | [Sequence]
H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Aib-Arg-NH2 |
| Hazard Information | Back Directory | [General Description]
Taspoglutide with -methylalanine in greatly retard degradation by DPP-IV and neutral endopeptidase24.11, respectively (see preceding discussion for exenatide).The phase III trials, which commenced in 2008, arebeing conducted with a zinc-based preparation, prolongingthe duration in a manner similar to zinc-containing insulinpreparations, so that once-weekly injections of 20 to 30 mgwill be possible. | [storage]
Store at -20°C |
|
|